KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to $23.0 million.

  • Fulgent Genetics' Accumulated Expenses fell 357.05% to $23.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.0 million, marking a year-over-year decrease of 357.05%. This contributed to the annual value of $24.3 million for FY2024, which is 2101.05% down from last year.
  • Latest data reveals that Fulgent Genetics reported Accumulated Expenses of $23.0 million as of Q3 2025, which was down 357.05% from $21.7 million recorded in Q2 2025.
  • Over the past 5 years, Fulgent Genetics' Accumulated Expenses peaked at $30.7 million during Q4 2023, and registered a low of $11.8 million during Q1 2022.
  • Its 5-year average for Accumulated Expenses is $22.7 million, with a median of $23.4 million in 2024.
  • In the last 5 years, Fulgent Genetics' Accumulated Expenses surged by 10943.64% in 2021 and then plummeted by 3560.85% in 2025.
  • Quarter analysis of 5 years shows Fulgent Genetics' Accumulated Expenses stood at $17.7 million in 2021, then surged by 41.22% to $25.0 million in 2022, then grew by 23.04% to $30.7 million in 2023, then decreased by 21.01% to $24.3 million in 2024, then decreased by 5.23% to $23.0 million in 2025.
  • Its Accumulated Expenses stands at $23.0 million for Q3 2025, versus $21.7 million for Q2 2025 and $16.7 million for Q1 2025.